Loading stock data…
West Pharmaceutical Services, I (WST)
$328.20-27.28 (-7.67%)
Market ClosedLast close Jul 24
West Pharmaceutical Services, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
West Pharmaceutical Services, Inc. in the Healthcare sector is trading at $328.20 with a market capitalization of $22.8B. Wall Street consensus targets $397.29 (14 analysts), implying a +21.0% move over the next 12 months. The stock is currently 15% below its 52-week high of $386.00, remaining 16.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $844.90M↑ | $805.00M | $804.60M↑ | $766.50M↑ | $698.00M |
| Gross Profit | $296.40M↓ | $303.90M↑ | $294.30M↑ | $273.90M↑ | $231.90M |
| Operating Income | $181.10M↑ | $175.10M↑ | $174.50M↑ | $158.90M↑ | $127.60M |
| Net Income | $138.80M↑ | $132.10M↓ | $140.00M↑ | $131.80M↑ | $89.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Pro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
43.13
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.27%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.15%
Volume
Today's trading volume
1.30M
Recent News
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.